NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
The Sydney Morning Herald - Oct 13, 2026
NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.